Update on hepatitis C: Direct-acting antivirals  

作　　者：Leon L Seifert Ryan B Perumpail Aijaz Ahmed 

机构地区：[1]Department of Transplantation Medicine,University Hospital Münster [2]Division of Gastroenterology and Hepatology, Stanford University School of Medicine

出　　处：《World Journal of Hepatology》2015年第28期2829-2833,共5页世界肝病学杂志（英文版）（电子版）

摘　　要：Hepatitis C virus(HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals(DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus. These drugs have revolutionized the management of HCV as all-oral regimens with favorable side effect profiles and superior rates of sustained virological response. Emerging real-world data are demonstrating results comparable to registration trials for DAA agents. Suddenly, the potential for eradicating HCV is on the horizon.Hepatitis C virus(HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals(DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus. These drugs have revolutionized the management of HCV as all-oral regimens with favorable side effect profiles and superior rates of sustained virological response. Emerging real-world data are demonstrating results comparable to registration trials for DAA agents. Suddenly, the potential for eradicating HCV is on the horizon.

关 键 词：HEPATITIS C VIRUS Direct-acting ANTIVIRALS SUSTAINED VIROLOGIC response Management Treatment 

分 类 号：R512.63[医药卫生—内科学]